New Study done by Dr. Phillip Bosch
Interstitial Cystitis continues to baffle the medical community in many ways.
Interstitial Cystitis also known as the painful bladder syndrome is a chronic and sometimes debilitating disease. The direct medical costs of taking care of a patient with Interstitial Cystitis is frequently more than $11,000.00 per year. This does not include the lost time from work and the decreased productivity.
None of the current treatments for Interstitial Cystitis work more than about 60% of the time. An article came out in the Journal of Urology this month. A novel application was attempted. The drug Adalimumab (Humira) has been approved to treat 7 different autoimmune diseases. The only other drugs that have been successful with autoimmune diseases are Methotrexate, Predisone, and Cyclosporine A. None of these drugs have been particularly effective with Interstitial Cystitis. A researcher, Dr. Phillip Bosch studied 43 patients and found that their symptomatology was greatly improved on a subcutaneous injection of 80 mg of Adalimumab followed by 40 mg injected every 2 weeks for 12 weeks.
As you might imagine, this therapy could be quite costly.
In the conclusions, Dr. Bosch concluded that the drug did not cause any serious side effects, but was not much better than the placebo in relieving symptoms.
The patients in the study responded well to the placebo.
So, once again, we are left with a concept that some of the IC patient's definitely do appear to have an autoimmune component. But, manipulation of that autoimmune reaction has proven repetitively to be clinically difficult. The author did recommend that the drug be studied further.